Literature DB >> 31750966

A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome.

Uday C Ghoshal1, Abhimanyu Nehra1, Akash Mathur1, Sushmita Rai1.   

Abstract

BACKGROUND: Enteric microbiota is increasingly being recognized as an important factor in the pathogenesis of irritable bowel syndrome (IBS). The reported prevalence of small intestinal bacterial overgrowth (SIBO) in subjects with IBS is highly variable, and there is no consensus on the role of SIBO in different subtypes of IBS, and indications and methods of testing.
METHODS: A comprehensive literature search was performed for studies applying tests for SIBO in subjects with IBS. After applying prospectively decided exclusion criteria, the eligible papers were examined using a meta-analysis approach for the prevalence of SIBO in subjects with IBS using different tests. The odds ratios of SIBO among subjects with IBS as compared with healthy controls using different tests were calculated.
RESULTS: Of the available studies (22, 17, 5, and 3 using lactulose and glucose hydrogen breath tests [LHBT and GHBT], jejunal aspirate culture, and more than one tests, respectively) meeting the inclusion criteria, 36.7% (95% confidence interval [CI] 24.2-44.6) had a positive test for SIBO. Patients with IBS were 2.6 (95% CI 1.3-6.9) and 8.3 (95% CI 3.0-5.9) times more likely to have a positive test for SIBO as compared with healthy controls using GHBT and jejunal aspirate culture, respectively. Patients with diarrhea-predominant IBS were more likely to have positive GHBT as compared with the other subtypes.
CONCLUSIONS: Patients with IBS were more likely to have SIBO as compared with healthy subjects using GHBT and jejunal aspirate culture but not using LHBT. Patients with diarrhea-predominant IBS more often have SIBO.
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  breath test; chronic diarrhea; culture; dysbiosis; functional bowel disease; gut microbiota; irritable bowel syndrome; rifaximin

Year:  2019        PMID: 31750966     DOI: 10.1111/jgh.14938

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Small intestinal bacterial overgrowth in patients with inflammatory bowel disease: A case-control study.

Authors:  Uday C Ghoshal; Ankur Yadav; Bushra Fatima; Anand Prakash Agrahari; Asha Misra
Journal:  Indian J Gastroenterol       Date:  2021-08-14

2.  Immune responses in the irritable bowel syndromes: time to consider the small intestine.

Authors:  Grace L Burns; Nicholas J Talley; Simon Keely
Journal:  BMC Med       Date:  2022-03-31       Impact factor: 8.775

Review 3.  Postinfection Irritable Bowel Syndrome.

Authors:  Uday C Ghoshal
Journal:  Gut Liver       Date:  2022-05-15       Impact factor: 4.519

4.  Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: An initiative of the Indian Neurogastroenterology and Motility Association.

Authors:  Uday C Ghoshal; Sanjeev Sachdeva; Ujjala Ghoshal; Asha Misra; Amarender Singh Puri; Nitesh Pratap; Ayesha Shah; M Masudur Rahman; Kok Ann Gwee; Victoria P Y Tan; Tahmeed Ahmed; Yeong Yeh Lee; B S Ramakrishna; Rupjyoti Talukdar; S V Rana; Saroj K Sinha; Minhu Chen; Nayoung Kim; Gerald Holtmann
Journal:  Indian J Gastroenterol       Date:  2022-10-10

5.  Faecal Microbiome Transplantation as a Solution to Chronic Enteropathies in Dogs: A Case Study of Beneficial Microbial Evolution.

Authors:  Michele Berlanda; Giada Innocente; Barbara Simionati; Barbara Di Camillo; Sonia Facchin; Maria Cecilia Giron; Edoardo Savarino; Federico Sebastiani; Francesca Fiorio; Ilaria Patuzzi
Journal:  Animals (Basel)       Date:  2021-05-17       Impact factor: 2.752

Review 6.  Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?

Authors:  Huw Purssell; Peter J Whorwell; Varinder S Athwal; Dipesh H Vasant
Journal:  World J Hepatol       Date:  2021-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.